Skip to content

Search...

About
- Our Mission
- Donors
- Board of Directors
- Advisory Boards
- Staff
- Careers
- Who we are
- FAQ
- Annual Report
Why New TB Drugs
R&D
Access
News

Search...

About
- Our Mission
- Donors
- Board of Directors
- Advisory Boards
- Staff
- Careers
- Who we are
- FAQ
- Annual Report
Why New TB Drugs
R&D
Access
News

Search...

About
- Our Mission
- Donors
- Board of Directors
- Advisory Boards
- Staff
- Careers
- Who we are
- FAQ
- Annual Report
Why New TB Drugs
R&D
Access
News

Search...

About
- Our Mission
- Donors
- Board of Directors
- Advisory Boards
- Staff
- Careers
- Who we are
- FAQ
- Annual Report
Why New TB Drugs
R&D
Access
News

Financial Statement

2016 TB Alliance Financial Statement

September 13, 2017

2015 TB Alliance Financial Statement

December 31, 2016

2014 TB Alliance Financial Statement

December 31, 2015

2013 TB Alliance Financial Statement

March 4, 2015

2012 TB Alliance Financial Statement

December 31, 2013

2011 TB Alliance Financial Statement

November 19, 2012

2010 TB Alliance Financial Statement

October 14, 2011

2009 TB Alliance Financial Statement

November 8, 2010

Click here to view TB Alliance financial information for the year ending December 31, 2009 Such financial statements are presented

2008 TB Alliance Financial Statement

December 2, 2009

Click here to view TB Alliance financial information for the year ending December 31, 2008 Such financial statements are

← Previous 1 2

About
Why New TB Drugs
R&D
Access
News

New York: 80 Pine Street, 20th floor, New York, NY 10005 • +1 212 227 7540

Johannesburg: Spaces Atrium on 5th, 9th Floor, 5th Street, Sandton, Johannesburg, 2196, South Africa • +27 12 991 6328

Press Inquiries

Jess Wiggs
p | +1 646 616 8613
e | jessica.wiggs@tballiance.org

Jobs

View job openings

Join our mailing list

Email Address

© 2025 The TB Alliance. All Rights Reserved. Report a Concern | Privacy Policy

In the first fifteen years following BPaL’s approval, more than 2 million people treated for drug-resistant TB will be treated with BPaL/M. This means millions of people will benefit from improved treatment outcomes and experiences.

BPaL/M has higher treatment success rates than previous therapies and use of these regimens is rapidly scaling up globally. In its first 15 years of approval, BPaL will save an additional 190,000 lives by replacing older treatments with lower success rates.

When TB doesn’t kill, it often leaves people with long periods of disability. By curing drug-resistant TB faster and more effectively, BPaL/M helps people not only survive, but recover faster, and avoid long term disabilities. That means fewer years lost to illness and more people living fully again, faster. In its first 15 years of approval, BPaL will result in people experiencing more than 5,000,000 more healthy years of life.

332,654 Additional Treatment Successes

People who do not complete treatment and/or follow-up are not considered to have successful treatment outcomes. Thus, additional treatment successes are about more than just “lives saved.” In its first 15 years of approval, BPaL/M will lead to more than 330,000 additional people with drug-resistant TB being successfully treated.

179,697 more people will complete treatment

Traditionally, many people receiving treatment for drug-resistant TB did not complete therapy. This was often due to the length and side effects of treatments. Those who don’t complete treatment may remain contagious and infect others, as well as suffer increased disability or death. In its first 15 years of approval, BPaL/M will lead to nearly 180,000 additional people completing treatment.

BPaL/M drastically reduces the cost of fighting drug-resistant TB for individuals, families, and governments. Hospital visits are fewer, and medicines are more affordable. As a result, in the first 15 years of approval, BPaL/M will save health systems nearly $1.3B globally. Shorter treatments also mean reduced out of pocket costs and time out of work for people getting treated.

BPaL/M drastically reduces the cost of fighting drug-resistant TB for individuals, families, and governments. Hospital visits are fewer, and medicines are more affordable. As a result, in the first 15 years of approval, BPaL/M will save health systems nearly $1.3B globally. Shorter treatments also mean reduced out of pocket costs and time out of work for people getting treated.

The BPaL/M treatment costs less than $2 per day, however the vast majority of cost savings from implementing these new regimens is achieved through shorter and simpler treatment, reducing human and financial burden on health systems. This allows for the expansion of DR-TB care where costs and human resources have previously limited health systems’ capacities to treat DR-TB.